冠状动脉介入术后患者血小板高反应性的影响因素分析(4)
[8]Agarwal S， Coakley M， Reddy K， et al. Quantifying the effect of antiplatelet therapy： a comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission[J]. Platelet，2006，105(4)：676-683.
[9]Lev E I， Patel R T， Maresh K J， et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention： the role of dual drug resistance[J]. J Am Coll Cardiol，2006，47(1)：27-33.
[10]Latif F， Kleiman NS， Cohen DJ， et al. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents： a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry[J]. JACC Cardiovascular interventions，2009，2(1)：37-45.
[11]Zaccardi F， Pitocco D， Willeit P， et al. Efficacy and safety of P2Y12 inhibitors according to diabetes， age， gender， body mass index and body weight： systematic review and meta-analyses of randomized clinical trials[J]. Atherosclerosis，2015，240(2)：439-445.
[12]Motovska Z， Widimsky P， Petr R， et al. Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention： statin's advantage and the smoking “paradox”[J]. J Cardiovascular pharmaco，2009，53(5)：368-372., http://www.100md.com(许盛松 郭玲玉 张明亮 周璇 张俊峰)
[9]Lev E I， Patel R T， Maresh K J， et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention： the role of dual drug resistance[J]. J Am Coll Cardiol，2006，47(1)：27-33.
[10]Latif F， Kleiman NS， Cohen DJ， et al. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents： a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry[J]. JACC Cardiovascular interventions，2009，2(1)：37-45.
[11]Zaccardi F， Pitocco D， Willeit P， et al. Efficacy and safety of P2Y12 inhibitors according to diabetes， age， gender， body mass index and body weight： systematic review and meta-analyses of randomized clinical trials[J]. Atherosclerosis，2015，240(2)：439-445.
[12]Motovska Z， Widimsky P， Petr R， et al. Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention： statin's advantage and the smoking “paradox”[J]. J Cardiovascular pharmaco，2009，53(5)：368-372., http://www.100md.com(许盛松 郭玲玉 张明亮 周璇 张俊峰)